Cargando…

Patient perspectives of artificial intelligence as a medical device in a skin cancer pathway

The use of artificial intelligence as a medical device (AIaMD) in healthcare systems is increasing rapidly. In dermatology, this has been accelerated in response to increasing skin cancer referral rates, workforce shortages and backlog generated by the COVID-19 pandemic. Evidence regarding patient p...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawsar, Anusuya, Hussain, Khawar, Kalsi, Dilraj, Kemos, Polychronis, Marsden, Helen, Thomas, Lucy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693417/
https://www.ncbi.nlm.nih.gov/pubmed/38046409
http://dx.doi.org/10.3389/fmed.2023.1259595
_version_ 1785153157003739136
author Kawsar, Anusuya
Hussain, Khawar
Kalsi, Dilraj
Kemos, Polychronis
Marsden, Helen
Thomas, Lucy
author_facet Kawsar, Anusuya
Hussain, Khawar
Kalsi, Dilraj
Kemos, Polychronis
Marsden, Helen
Thomas, Lucy
author_sort Kawsar, Anusuya
collection PubMed
description The use of artificial intelligence as a medical device (AIaMD) in healthcare systems is increasing rapidly. In dermatology, this has been accelerated in response to increasing skin cancer referral rates, workforce shortages and backlog generated by the COVID-19 pandemic. Evidence regarding patient perspectives of AIaMD is currently lacking in the literature. Patient acceptability is fundamental if this novel technology is to be effectively integrated into care pathways and patients must be confident that it is implemented safely, legally, and ethically. A prospective, single-center, single-arm, masked, non-inferiority, adaptive, group sequential design trial, recruited patients referred to a teledermatology cancer pathway. AIaMD assessment of dermoscopic images were compared with clinical or histological diagnosis, to assess performance (NCT04123678). Participants completed an online questionnaire to evaluate their views regarding use of AIaMD in the skin cancer pathway. Two hundred and sixty eight responses were received between February 2020 and August 2021. The majority of respondents were female (57.5%), ranged in age between 18 and 93 years old, Fitzpatrick type I-II skin (81.3%) and all 6 skin types were represented. Overall, there was a positive sentiment regarding potential use of AIaMD in skin cancer pathways. The majority of respondents felt confident in computers being used to help doctors diagnose and formulate management plans (median = 70; interquartile range (IQR) = 50–95) and as a support tool for general practitioners when assessing skin lesions (median = 85; IQR = 65–100). Respondents were comfortable having their photographs taken with a mobile phone device (median = 95; IQR = 70–100), which is similar to other studies assessing patient acceptability of teledermatology services. To the best of our knowledge, this is the first comprehensive study evaluating patient perspectives of AIaMD in skin cancer pathways in the UK. Patient involvement is essential for the development and implementation of new technologies. Continued end-user feedback will allow refinement of services to ensure patient acceptability. This study demonstrates patient acceptability of the use of AIaMD in both primary and secondary care settings.
format Online
Article
Text
id pubmed-10693417
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106934172023-12-03 Patient perspectives of artificial intelligence as a medical device in a skin cancer pathway Kawsar, Anusuya Hussain, Khawar Kalsi, Dilraj Kemos, Polychronis Marsden, Helen Thomas, Lucy Front Med (Lausanne) Medicine The use of artificial intelligence as a medical device (AIaMD) in healthcare systems is increasing rapidly. In dermatology, this has been accelerated in response to increasing skin cancer referral rates, workforce shortages and backlog generated by the COVID-19 pandemic. Evidence regarding patient perspectives of AIaMD is currently lacking in the literature. Patient acceptability is fundamental if this novel technology is to be effectively integrated into care pathways and patients must be confident that it is implemented safely, legally, and ethically. A prospective, single-center, single-arm, masked, non-inferiority, adaptive, group sequential design trial, recruited patients referred to a teledermatology cancer pathway. AIaMD assessment of dermoscopic images were compared with clinical or histological diagnosis, to assess performance (NCT04123678). Participants completed an online questionnaire to evaluate their views regarding use of AIaMD in the skin cancer pathway. Two hundred and sixty eight responses were received between February 2020 and August 2021. The majority of respondents were female (57.5%), ranged in age between 18 and 93 years old, Fitzpatrick type I-II skin (81.3%) and all 6 skin types were represented. Overall, there was a positive sentiment regarding potential use of AIaMD in skin cancer pathways. The majority of respondents felt confident in computers being used to help doctors diagnose and formulate management plans (median = 70; interquartile range (IQR) = 50–95) and as a support tool for general practitioners when assessing skin lesions (median = 85; IQR = 65–100). Respondents were comfortable having their photographs taken with a mobile phone device (median = 95; IQR = 70–100), which is similar to other studies assessing patient acceptability of teledermatology services. To the best of our knowledge, this is the first comprehensive study evaluating patient perspectives of AIaMD in skin cancer pathways in the UK. Patient involvement is essential for the development and implementation of new technologies. Continued end-user feedback will allow refinement of services to ensure patient acceptability. This study demonstrates patient acceptability of the use of AIaMD in both primary and secondary care settings. Frontiers Media S.A. 2023-11-16 /pmc/articles/PMC10693417/ /pubmed/38046409 http://dx.doi.org/10.3389/fmed.2023.1259595 Text en Copyright © 2023 Kawsar, Hussain, Kalsi, Kemos, Marsden and Thomas. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Kawsar, Anusuya
Hussain, Khawar
Kalsi, Dilraj
Kemos, Polychronis
Marsden, Helen
Thomas, Lucy
Patient perspectives of artificial intelligence as a medical device in a skin cancer pathway
title Patient perspectives of artificial intelligence as a medical device in a skin cancer pathway
title_full Patient perspectives of artificial intelligence as a medical device in a skin cancer pathway
title_fullStr Patient perspectives of artificial intelligence as a medical device in a skin cancer pathway
title_full_unstemmed Patient perspectives of artificial intelligence as a medical device in a skin cancer pathway
title_short Patient perspectives of artificial intelligence as a medical device in a skin cancer pathway
title_sort patient perspectives of artificial intelligence as a medical device in a skin cancer pathway
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693417/
https://www.ncbi.nlm.nih.gov/pubmed/38046409
http://dx.doi.org/10.3389/fmed.2023.1259595
work_keys_str_mv AT kawsaranusuya patientperspectivesofartificialintelligenceasamedicaldeviceinaskincancerpathway
AT hussainkhawar patientperspectivesofartificialintelligenceasamedicaldeviceinaskincancerpathway
AT kalsidilraj patientperspectivesofartificialintelligenceasamedicaldeviceinaskincancerpathway
AT kemospolychronis patientperspectivesofartificialintelligenceasamedicaldeviceinaskincancerpathway
AT marsdenhelen patientperspectivesofartificialintelligenceasamedicaldeviceinaskincancerpathway
AT thomaslucy patientperspectivesofartificialintelligenceasamedicaldeviceinaskincancerpathway